Nucresiran Clinical Trials (2026): 2 Studies for hATTR-PN & Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

Where to Participate: All Nucresiran Trial Sites in the U.S. (47 sites across 24 states)

Every actively recruiting Nucresirantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Nucresiran clinical trials at a glance: phase × recruitment status

Recruiting Nucresiran clinical trials (2)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Nucresiran clinical trials by indication

Nucresiran pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

All Nucresiran trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Nucresiran clinical trials: frequently asked questions

How many Nucresiran clinical trials are there?

2 Nucresiran clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.

Are Nucresiran clinical trials recruiting in 2026?

Yes — 2 Nucresiran trials are actively recruiting in 2026, with 47 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Nucresiran being studied for?

Nucresiran is being studied for hATTR-PN, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, Transthyretin Amyloidosis With Cardiomyopathy. The trials are grouped by indication on this page.

What phase is Nucresiran in?

Nucresiran clinical trials span 2 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Nucresiran clinical trials?

The lead sponsor across the most Nucresiran trials is Alnylam Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nucresiranas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed July 17, 2026.